Literature DB >> 12952255

Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis.

V Cottin1, F Thivolet-Béjui, M Reynaud-Gaubert, J Cadranel, P Delaval, P J Ternamian, J F Cordier.   

Abstract

This study investigated interstitial pneumonia associated with amyopathic dermatomyositis, dermatomyositis and polymyositis, paying particular attention to muscular and/or cutaneous manifestations and their chronology relative to lung involvement. Patients included four males and 13 females, aged 51.7+/-10.8 yrs, who had surgical lung biopsy. Diagnoses included dermatomyositis (10 patients), polymyositis (four patients) and amyopathic dermatomyositis (three patients). Solitary respiratory manifestations preceded the onset of any skin or muscle disease in four cases (24%). Reticular and ground glass opacities were the most frequent computed tomography (CT) findings. Pathological review showed nonspecific interstitial pneumonia (eleven, 65%; cellular, two; cellular and fibrotic, five; fibrotic, four), usual interstitial pneumonia (two), organising pneumonia (two), lymphocytic interstitial pneumonia (one), and unclassifiable interstitial pneumonia (one). Nonspecific interstitial pneumonia was the most common histological pattern of interstitial pneumonia in patients with amyopathic dermatomyositis (three of three) and in patients with respiratory symptoms as the initial clinical manifestation of the connective tissue disease (three of four). Survival at 5 yrs was 50%. This study shows the clinician should remain alert to potential muscular or cutaneous manifestations whenever a pathological diagnosis of nonspecific interstitial pneumonia is made.

Entities:  

Mesh:

Year:  2003        PMID: 12952255     DOI: 10.1183/09031936.03.00026703

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  48 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

2.  Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations.

Authors:  Pamela A Morganroth; Mary Elizabeth Kreider; Joyce Okawa; Lynne Taylor; Victoria P Werth
Journal:  Arch Dermatol       Date:  2010-07

3.  Interstitial lung disease in a patient with antisynthetase syndrome and no myositis.

Authors:  Sotiris C Plastiras; Fotini C Soliotis; Panayiotis Vlachoyiannopoulos; George E Tzelepis
Journal:  Clin Rheumatol       Date:  2005-11-23       Impact factor: 2.980

Review 4.  Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.

Authors:  Aryeh Fischer; Jörg Distler
Journal:  Clin Rheumatol       Date:  2019-08-19       Impact factor: 2.980

5.  Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis.

Authors:  Eishi Miyazaki; Masaru Ando; Tomoko Muramatsu; Tetsujiro Fukami; Osamu Matsuno; Shin-Ichi Nureki; Takuya Ueno; Tomiyasu Tsuda; Toshihide Kumamoto
Journal:  Clin Rheumatol       Date:  2005-12-20       Impact factor: 2.980

Review 6.  Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review.

Authors:  Bornstein Gil; Lidar Merav; Langevitz Pnina; Grossman Chagai
Journal:  Clin Rheumatol       Date:  2015-04-07       Impact factor: 2.980

Review 7.  Amyopathic dermatomyositis: definitions, diagnosis, and management.

Authors:  Elizabeth E Bailey; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

8.  Spontaneous pneumomediastinum: an unusual but serious complication of dermatomyositis.

Authors:  John Alexander; Stuart Packham; Gillian Warwick; Lekshmi Mohan Das
Journal:  BMJ Case Rep       Date:  2014-11-25

9.  AJRCCM: 100-Year Anniversary. Progress in Interstitial Lung Disease.

Authors:  Robert J Kaner; Kevin K Brown; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2017-05-01       Impact factor: 21.405

Review 10.  Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Authors:  Tsuneyo Mimori; Ran Nakashima; Yuji Hosono
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.